Literature DB >> 18704411

Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding beta2-microglobulin genes.

Chin-Hsuan Hsieh1, Ya-Jan Hsu, Chien-Chung Chang, Hsin-Chun Liu, Kun-Lung Chuang, Cheng-Keng Chuang, See-Tong Pang, Kenichiro Hasumi, Soldano Ferrone, Shuen-Kuei Liao.   

Abstract

In renal cell carcinoma (RCC), HLA class I downregulation has been found in about 40% of the lesions examined. Since only scanty information is available about the molecular basis of these defects, we have investigated the mechanism(s) underlying HLA class I antigen downregulation or loss in six RCC cell lines. Five of them express HLA class I antigens although at various levels; on the other hand, HLA class I antigens are not detectable on the remaining cell line, the RCC52 cell line, belonging to a sarcomatoid subtype, even following incubation with IFN-gamma. beta(2)-microglobulin (beta(2) m) was not detected in RCC52 cells. Surprisingly, RCC52 cells harbor two mutations in the beta ( 2 ) m genes in exon 1: a single G deletion (delG) in codon 6, which introduces a premature stop at codon 7, and a CT dinucleotide deletion (delCT), which leads to a premature stop at codon 55. Analysis of eight clonal sublines isolated from the RCC52 cell line showed that the two beta ( 2 ) m gene mutations are carried separately by RCC52 cell subpopulations. The delG/delCT double mutations were detected in two sublines with a fibroblast-like morphology, while the delCT mutation was detected in the remaining six sublines with an epithelial cell morphology. Furthermore, loss of heterozygosity (LOH) of the beta ( 2 ) m gene at STR D15S-209 was found only in the epithelioid subpopulation, indicating loss of one copy of chromosome 15. Immunostaining results of the tumor lesion from which the cell line RCC52 was originated were consistent with the phenotyping/molecular findings of the cultured cells. This is the first example of the coexistence of distinct beta ( 2 ) m defects in two different tumor subpopulations of a RCC, where loss of one copy of chromosome 15 occurs in one of the subpopulations with total HLA class I antigen loss.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18704411      PMCID: PMC2793116          DOI: 10.1007/s00262-008-0565-7

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  35 in total

1.  Modified flow cytometry and cell-ELISA methodology to detect HLA class I antigen processing machinery components in cytoplasm and endoplasmic reticulum.

Authors:  Takeshi Ogino; Xinhui Wang; Soldano Ferrone
Journal:  J Immunol Methods       Date:  2003-07       Impact factor: 2.303

2.  The interrelationship of hematogenous and lymphatic tumor cell dissemination: an experimental study.

Authors:  B Fisher; E R Fisher
Journal:  Rev Inst Nac Cancerol (Mex)       Date:  1966-12

Review 3.  Review of sarcomatoid renal cell carcinoma with focus on clinical and pathobiological aspects.

Authors:  N Kuroda; M Toi; M Hiroi; H Enzan
Journal:  Histol Histopathol       Date:  2003-04       Impact factor: 2.303

4.  Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.

Authors:  Zhen Su; Jens Dannull; Axel Heiser; Donna Yancey; Scott Pruitt; John Madden; Doris Coleman; Donna Niedzwiecki; Eli Gilboa; Johannes Vieweg
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

5.  Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors.

Authors:  C M Cabrera; P Jiménez; T Cabrera; C Esparza; F Ruiz-Cabello; F Garrido
Journal:  Tissue Antigens       Date:  2003-03

6.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis.

Authors:  C J Barnstable; W F Bodmer; G Brown; G Galfre; C Milstein; A F Williams; A Ziegler
Journal:  Cell       Date:  1978-05       Impact factor: 41.582

7.  Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?

Authors:  Derek Atkins; Soldano Ferrone; Gerd E Schmahl; Stefan Störkel; Barbara Seliger
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

8.  The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis.

Authors:  Chengsen Xue; David Plieth; Christo Venkov; Carol Xu; Eric G Neilson
Journal:  Cancer Res       Date:  2003-06-15       Impact factor: 12.701

9.  Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide.

Authors:  Federico Perosa; Grazia Luccarelli; Marcella Prete; Elvira Favoino; Soldano Ferrone; Franco Dammacco
Journal:  J Immunol       Date:  2003-08-15       Impact factor: 5.422

10.  Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.

Authors:  Hardev S Pandha; Robert J John; James Hutchinson; Nick James; Mike Whelan; Catherine Corbishley; Angus G Dalgleish
Journal:  BJU Int       Date:  2004-08       Impact factor: 5.588

View more
  3 in total

Review 1.  Therapeutic cancer vaccines: current status and moving forward.

Authors:  Jeffrey Schlom
Journal:  J Natl Cancer Inst       Date:  2012-03-06       Impact factor: 13.506

2.  Differential expression of CD44 and CD24 markers discriminates the epitheliod from the fibroblastoid subset in a sarcomatoid renal carcinoma cell line: evidence suggesting the existence of cancer stem cells in both subsets as studied with sorted cells.

Authors:  Chin-Hsuan Hsieh; Shih-Chieh Hsiung; Chi-Tai Yeh; Chih-Feng Yen; Yah-Huei Wu Chou; Wei-Yi Lei; See-Tong Pang; Cheng-Keng Chuang; Shuen-Kuei Liao
Journal:  Oncotarget       Date:  2017-02-28

3.  Relationship between major histocompatibility complex class I expression and prognosis in canine mammary gland tumors.

Authors:  Toshiyuki Tanaka; Terumasa Shimada; Hideo Akiyoshi; Junichiro Shimizu; Cao Zheng; Li Yijyun; Keiichiro Mie; Akiyoshi Hayashi; Mitsuru Kuwamura; Fumio Hoshi; Fumihito Ohashi
Journal:  J Vet Med Sci       Date:  2013-05-31       Impact factor: 1.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.